Goodpasture syndrome secondary prevention
Goodpasture syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Goodpasture syndrome secondary prevention On the Web |
American Roentgen Ray Society Images of Goodpasture syndrome secondary prevention |
Risk calculators and risk factors for Goodpasture syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]
Overview
Effective measures for the secondary prevention of Goodpasture syndrome include patient education. Patients should be educated about the signs and symptoms of renal dysfunction as certain steroid and immunosuppressive therapy may have adverse effects on the kidneys. Patients should be monitored regularly for renal function and those with severe dysfunction should have be referred for dialysis.
Secondary Prevention
Effective measures for the secondary prevention of Goodpasture syndrome include:[1][2][3][4]
- Patient education: Patient education is an important aspect in early diagnosis and management of Goodpasture syndrome.
- Patients with lung involvement should be strictly advised against smoking to prevent recurrent pulmonary hemorrhage.
- Patients should be educated about the signs and symptoms of renal dysfunction as certain steroid and immunosuppressive therapy may have adverse effects on the kidneys.
- Patients should be monitored regularly for renal function and dose adjustment of medications.
- Patients with severe renal dysfunction require long term dialysis and should be advised to seek medical care on a timely basis.
- Patients with deteriorating renal function despite maximal medical therapy should be put on renal transplantation list and patients should be informed that Goodpasture syndrome may even recur in the transplanted kidney, although it is very rare.
References
- ↑ Kluth DC, Rees AJ (November 1999). "Anti-glomerular basement membrane disease". J. Am. Soc. Nephrol. 10 (11): 2446–53. PMID 10541306.
- ↑ Menn-Josephy H, Beck LH (2015). "Recurrent glomerular disease in the kidney allograft". Front Biosci (Elite Ed). 7: 135–48. PMID 25553369.
- ↑ "Notice". Kidney Int Suppl (2011). 2 (2): 139. 2012. doi:10.1038/kisup.2012.9. PMC 4089568. PMID 25028634.
- ↑ Chen M, Kallenberg CG (2010). "ANCA-associated vasculitides--advances in pathogenesis and treatment". Nat Rev Rheumatol. 6 (11): 653–64. doi:10.1038/nrrheum.2010.158. PMID 20924413.